GO:0002532 production of molecular mediator involved in inflammatory response: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002532 describes the synthesis or release of any molecular mediator that drives the inflammatory response, leading to increased intracellular or extracellular levels of that mediator [1,3].
• Key molecular mediators include cytokines, chemokines, eicosanoids, bioactive sphingolipids, complement proteins, and type III interferons [5,6,7].
• This process is central to innate immunity and is dysregulated in chronic inflammatory diseases, fibrosis, neurodegeneration, and acute-on-chronic liver failure [1,3,8].
• Macrophages and microglia are major producers of inflammatory mediators, and their polarization states influence the profile of mediators released [1,2].
• CRISPR knockout, knock-in, point mutation, and overexpression models enable causal dissection of genes controlling mediator production [1,2,5].
• Targeting mediator production pathways offers therapeutic opportunities in inflammatory and metabolic disorders [3,4,6].
Description
The Gene Ontology term GO:0002532, production of molecular mediator involved in inflammatory response, defines the synthesis or release of any molecular mediator of the inflammatory response following an inflammatory stimulus, resulting in an increase in its intracellular or extracellular levels [1,3]. This process is a cornerstone of innate immunity and encompasses the generation of cytokines, chemokines, lipid mediators, complement components, and interferons that orchestrate tissue responses to infection and injury [5,6,7]. Researchers study this term to understand how inflammatory mediators are produced, how production is regulated, and how dysregulation contributes to disease [1,3,8]. The term is distinct from downstream signaling or cellular responses; it specifically covers the production step that elevates mediator levels [1,3]. Because many inflammatory diseases involve excessive or persistent mediator production, this GO term is highly relevant for drug discovery and biomarker development [3,4,6].
production of molecular mediator involved in inflammatory response At A Glance
| GO ID | GO:0002532 |
|---|---|
| GO term | production of molecular mediator involved in inflammatory response |
| Ontology | biological_process |
| Synonym | production of cellular mediator of acute inflammation; production of molecular mediator involved in acute inflammatory response |
| Major function | Synthesis or release of molecular mediators that drive inflammation, increasing their intracellular or extracellular levels [1,3] |
| Mediator types | Cytokines, chemokines, eicosanoids, sphingolipids, complement proteins, interferons [5,6,7] |
| Cellular sources | Macrophages, microglia, endothelial cells, epithelial cells, hepatocytes [1,2,3] |
| Stimuli | Pathogen-associated molecular patterns, damage-associated molecular patterns, cytokines [1,4] |
| Related diseases | Pulmonary fibrosis, Alzheimer's disease, acute-on-chronic liver failure, inflammatory skin diseases [1,3,7,8] |
What Is GO:0002532?
In our own words, GO:0002532 refers to the cellular processes that synthesize or release molecular mediators of inflammation after an inflammatory trigger, leading to higher amounts of these mediators inside or outside the cell. It includes the production of cytokines, chemokines, lipid mediators, and other bioactive molecules that propagate inflammatory responses [1,3,6].
Why Is production of molecular mediator involved in inflammatory response Important in Cell Biology?
Understanding GO:0002532 is critical because the production of inflammatory mediators is a central node in both protective immunity and pathological inflammation. Dysregulated mediator production contributes to chronic inflammatory diseases, fibrosis, neurodegeneration, and metabolic disorders [1,3,4,8]. Targeting the synthesis or release of specific mediators can reduce tissue damage while preserving host defense, making this process a prime therapeutic focus [3,6].
• Mediator production is required for recruiting immune cells to sites of infection or injury [1,4].
• Excessive production of cytokines and lipid mediators drives chronic inflammatory diseases [1,3,6].
• Macrophage polarization states alter the profile of mediators produced, affecting disease outcomes [1,2].
• Bioactive sphingolipids such as ceramide and sphingosine-1-phosphate modulate inflammatory mediator release.
• Complement activation products are molecular mediators in inflammatory skin diseases.
• Type III interferons are mediators with antiviral and immunomodulatory functions.
• In Alzheimer's disease, inflammatory mediator production contributes to neuroinflammation.
• In acute-on-chronic liver failure, systemic inflammatory mediators predict outcome.
• Hypertension involves innate immune mediator production that promotes vascular dysfunction.
• CRISPR screens can identify genes that regulate mediator production, revealing new drug targets [1,2,5].
What Happens During production of molecular mediator involved in inflammatory response?
Recognition of inflammatory stimuli
In simple terms: Cells sense danger signals from microbes or damaged tissue.
Inflammatory mediator production begins when pattern recognition receptors detect pathogen-associated molecular patterns or damage-associated molecular patterns. This triggers intracellular signaling cascades that activate transcription factors such as NF-kB and IRFs, leading to gene expression of mediators [1,4]. In macrophages and microglia, this recognition step is essential for subsequent mediator release [1,2].
Transcriptional induction of mediator genes
In simple terms: The cell turns on genes that code for inflammatory molecules.
Activated transcription factors drive the expression of genes encoding cytokines, chemokines, complement components, and interferon subtypes. For example, type III interferons are induced upon viral recognition and act as mediators. In acute-on-chronic liver failure, systemic inflammatory responses involve transcriptional upregulation of multiple mediators.
Synthesis and post-translational processing
In simple terms: The cell builds and modifies the mediator proteins or lipids.
Many mediators require post-translational processing for activity. Cytokines are synthesized as precursors and cleaved by proteases; lipid mediators such as eicosanoids and sphingolipids are generated by enzymatic cascades. Complement proteins undergo proteolytic activation to become active mediators.
Release and extracellular accumulation
In simple terms: Mediators are exported to act on other cells.
Mediators are released via classical secretion, exocytosis, or membrane transporters. This release increases extracellular levels, allowing mediators to bind receptors on target cells and amplify inflammation [1,3]. In pulmonary fibrosis, macrophage-derived mediators are released into the lung microenvironment.
Regulation and resolution
In simple terms: The process is controlled to avoid excessive damage.
Mediator production is tightly regulated by negative feedback loops, anti-inflammatory cytokines, and metabolic checkpoints. For instance, Nrf2 activation attenuates inflammatory mediator production in microglia and macrophages. Dysregulation of these control mechanisms leads to chronic inflammation [3,6].
Key Genes Involved in GO:0002532 production of molecular mediator involved in inflammatory response
The following genes and proteins are central to the production of molecular mediators involved in inflammatory responses, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NFKB1 | Transcription factor driving expression of many inflammatory mediators | Knockout reduces cytokine production [1,3] |
| RELA | NF-kB subunit; activates mediator gene transcription | Point mutations alter DNA binding |
| IL6 | Cytokine mediator of acute inflammation | Overexpression models chronic inflammation |
| TNF | Pro-inflammatory cytokine mediator | Knockout mice show reduced inflammation [1,4] |
| IL1B | Cytokine mediator; requires inflammasome processing | Point mutation affects secretion |
| CCL2 | Chemokine recruiting monocytes/macrophages | Knock-in reporters track production |
| CXCL8 | Chemokine mediating neutrophil recruitment | Knockout reduces neutrophil influx |
| PTGS2 | Enzyme producing prostaglandin mediators | Overexpression increases eicosanoids |
| ALOX5 | Enzyme producing leukotriene mediators | Knockout alters lipid mediator profile |
| SPHK1 | Enzyme producing sphingosine-1-phosphate | Knock-in tags enzyme for imaging |
| C3 | Complement component; precursor of mediators | Knockout impairs complement activation |
| C5 | Complement component generating C5a mediator | Point mutation affects cleavage |
| IFNL1 | Type III interferon mediator | Overexpression enhances antiviral state |
| IFNL2 | Type III interferon mediator | Knockout reduces interferon response |
| NLRP3 | Inflammasome sensor promoting IL-1b production | Point mutation causes autoinflammation |
| NFE2L2 | Transcription factor Nrf2; suppresses mediator production | Knockout increases inflammation |
| MAPK14 | Kinase regulating cytokine synthesis | Knock-in for activity tracking |
How Is production of molecular mediator involved in inflammatory response Regulated?
The production of molecular mediators involved in inflammatory responses is regulated at multiple levels. Transcriptional control by NF-kB, AP-1, and IRFs determines which mediators are made [1,3]. Post-transcriptional mechanisms, including mRNA stability and microRNAs, fine-tune mediator levels; macrophage-derived miRNAs modulate pulmonary fibrosis. Metabolic and oxidative stress pathways, such as Nrf2, suppress excessive mediator production. Lipid signaling pathways, including sphingolipid metabolism, also regulate mediator release. In disease, loss of these regulatory checkpoints leads to persistent inflammation [3,4].
production of molecular mediator involved in inflammatory response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL6 | Acute-on-chronic liver failure | Knockout hepatocytes |
| CCL2 | Pulmonary fibrosis | Knock-in reporter macrophages |
| C3 | Inflammatory skin diseases | Knockout keratinocytes |
| NFE2L2 | Neuroinflammation | Point mutation microglia |
| IFNL1 | Viral infections | Overexpression epithelial cells |
Pulmonary fibrosis
In pulmonary fibrosis, macrophages produce profibrotic mediators that drive fibroblast activation and matrix deposition. Macrophage polarization and macrophage-derived miRNAs influence the production of these mediators, making them therapeutic targets.
Acute-on-chronic liver failure
Systemic inflammatory mediator production is a hallmark of acute-on-chronic liver failure. Elevated levels of cytokines and chemokines correlate with disease severity and organ failure, and metabolic responses intersect with inflammatory pathways.
Alzheimer's disease
In Alzheimer's disease, microglia and astrocytes produce inflammatory mediators that contribute to neuroinflammation and neuronal damage. Molecular aspects of these inflammatory and immune responses have been characterized in brain tissue.
Inflammatory skin diseases
Complement activation generates mediators such as C3a and C5a that promote inflammation in skin diseases like psoriasis and urticaria. Targeting complement-mediated mediator production is a therapeutic strategy.
From production of molecular mediator involved in inflammatory response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate cytokine production? | CRISPR knockout in macrophages |
| Does a point mutation alter mediator release? | CRISPR point mutation in microglia |
| Can we track mediator production in real time? | Knock-in fluorescent reporter |
| Does overexpression of gene Y increase inflammation? | CRISPR overexpression in epithelial cells |
| Which genes control lipid mediator synthesis? | CRISPR library screening |
| Does complement activation drive skin inflammation? | Knockout mouse models |
How to Study the production of molecular mediator involved in inflammatory response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of mediator genes | Transcriptional profiling |
| Proteomics | Protein levels of mediators | Secretome analysis |
| Cytokine array | Multiple secreted cytokines | Screening inflammatory stimuli |
| Lipidomics | Bioactive lipid mediators | Eicosanoid and sphingolipid profiling |
| ELISA | Specific mediator concentration | Validation of production |
| Flow cytometry | Intracellular cytokine staining | Single-cell analysis |
| Live-cell imaging | Real-time mediator release | Reporter knock-in models |
Transcriptomic profiling
RNA-seq measures global changes in mediator gene expression after inflammatory stimulation. This identifies transcriptional programs and alternative splicing events that regulate mediator production [1,3].
Proteomic and cytokine arrays
Proteomics and cytokine antibody arrays quantify secreted mediators in culture supernatants or serum, providing a comprehensive view of mediator release [3,6].
Lipid mediator analysis
Mass spectrometry-based lipidomics detects eicosanoids, sphingolipids, and other bioactive lipids produced during inflammation.
Imaging and reporter assays
Fluorescent reporters knocked into mediator genes allow live-cell imaging of production and release. This is useful for studying dynamics in macrophages and microglia [1,2].
How CRISPR Can Be Used to Study GO:0002532 production of molecular mediator involved in inflammatory response
Knockout
CRISPR knockout of genes such as IL6, TNF, or CCL2 in macrophages or epithelial cells can determine whether they are required for production of specific mediators. This approach is widely used to validate targets in inflammation research [1,3].
Point Mutation
Point mutations introduced by CRISPR base editing or HDR can mimic disease-associated variants in mediator genes or their regulatory regions. For example, mutations in NLRP3 affect IL-1b production.
Knock-in
Knock-in of fluorescent or epitope tags into mediator genes allows tracking of endogenous protein production and release. This is valuable for studying dynamics in live cells [1,2].
Overexpression
CRISPR activation or cDNA overexpression can drive excessive mediator production to model chronic inflammation. Overexpressing IFNL1, for instance, enhances antiviral responses.
How EDITGENE Supports production of molecular mediator involved in inflammatory response Research
Researchers studying production of molecular mediator involved in inflammatory response-related genes often need to determine whether a candidate gene is causally involved in mediator synthesis or release. EDITGENE provides CRISPR-based cell model services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for production of molecular mediator involved in inflammatory response research.
Frequently Asked Questions About production of molecular mediator involved in inflammatory response
What is GO:0002532?
GO:0002532 is the Gene Ontology term for the synthesis or release of any molecular mediator of the inflammatory response, leading to increased intracellular or extracellular levels of that mediator [1,3].
What genes are involved in production of molecular mediator involved in inflammatory response?
Key genes include NFKB1, RELA, IL6, TNF, IL1B, CCL2, CXCL8, PTGS2, ALOX5, SPHK1, C3, C5, IFNL1, IFNL2, NLRP3, and NFE2L2 [1,2,3,5,6,7].
What are molecular mediators of inflammation?
They include cytokines, chemokines, eicosanoids, bioactive sphingolipids, complement proteins, and interferons [5,6,7].
How is production of inflammatory mediators regulated?
It is regulated transcriptionally by NF-kB and IRFs, post-transcriptionally by miRNAs, and metabolically by Nrf2 and sphingolipid pathways [1,2,6].
Which diseases involve dysregulated inflammatory mediator production?
Pulmonary fibrosis, acute-on-chronic liver failure, Alzheimer's disease, inflammatory skin diseases, and hypertension [1,3,4,7,8].
What cell types produce inflammatory mediators?
Macrophages, microglia, endothelial cells, epithelial cells, and hepatocytes are major producers [1,2,3].
How can CRISPR help study inflammatory mediator production?
CRISPR knockout, knock-in, point mutation, and overexpression models allow causal testing of genes in mediator synthesis and release [1,2,5].
What methods measure inflammatory mediator production?
RNA-seq, proteomics, cytokine arrays, lipidomics, ELISA, flow cytometry, and live-cell imaging [1,3,6].
What is the role of complement in inflammatory mediator production?
Complement activation generates mediators like C3a and C5a that amplify inflammation in skin diseases.
What is the role of type III interferons in inflammation?
Type III interferons are mediators with antiviral and immunomodulatory functions produced upon viral recognition.
Conclusion
GO:0002532 captures a central biological process in inflammation: the production of molecular mediators that amplify and sustain immune responses. Understanding its regulation and dysregulation is essential for developing therapies for chronic inflammatory diseases [1,3,6]. CRISPR-based models and multi-omics methods provide powerful tools to dissect this process and identify new targets [1,2,5].
References
- 1. Kishore A et al.. 2021. Roles of Macrophage Polarization and Macrophage-Derived miRNAs in Pulmonary Fibrosis.. Front Immunol 12:678457 PMID: 34489932
- 2. Cui Y et al.. 2021. Microglia and macrophage exhibit attenuated inflammatory response and ferroptosis resistance after RSL3 stimulation via increasing Nrf2 expression.. J Neuroinflammation 18(1):249 PMID: 34717678
- 3. Clària J et al.. 2023. Roles of systemic inflammatory and metabolic responses in the pathophysiology of acute-on-chronic liver failure.. JHEP Rep 5(9):100807 PMID: 37600957
- 4. De Sanctis JB. 2022. Innate Immune Response in Hypertension.. Curr Pharm Des 28(36):2984-2990 PMID: 36154596
- 5. Kotenko SV et al.. 2019. Type III IFNs: Beyond antiviral protection.. Semin Immunol 43:101303 PMID: 31771761
- 6. El Alwani M et al.. 2006. Bioactive sphingolipids in the modulation of the inflammatory response.. Pharmacol Ther 112(1):171-83 PMID: 16759708
- 7. Giang J et al.. 2018. Complement Activation in Inflammatory Skin Diseases.. Front Immunol 9:639 PMID: 29713318
- 8. Kalaria RN et al.. 1996. Molecular aspects of inflammatory and immune responses in Alzheimer's disease.. Neurobiol Aging 17(5):687-93 PMID: 8892341
